ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2170

Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays

Makoto Miyara1, Rémi Chieze2, Yurdagul Uzunhan3, Jean- Luc Charuel4, Pascale Ghillani-Dalbin4, Sasi Mudumba5, Alice Wu5, Hilario Nunes3, Zahir Amoura6, Rufus Burlingame5 and Lucile Musset1, 1Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 2department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 3Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, 4Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 5Genalyte Inc., San Diego, CA, 6Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, dermatomyositis, diagnosis and interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The presence of anti-MDA5 antibody is associated with amyopathic dermatomyositis and/or rapidly progressive interstitial lung disease that can be fatal.In the latter case, it is mandatory to confirm the diagnosis as soon as possible in order to initiate aggressive treatments and the presence of anti-MDA5 autoantibodies is an important part of the differential diagnosis. The immunoassay using photonic microrings is a new sensitive technology that enables rapid results in less than 15 minutes. The aim of our study was to evaluate this technology for the detection of anti-MDA5 antibodies in sera with known positivity.

Methods: The system is based on immobilizing the antigenic target, MDA5, above the photonic rings in a silicon chip. We analyzed a total of 72 sera drawn from 40 patients known to be positive for anti-MDA5 antibody in our laboratory using immunoblotting assays and 4 negative controls. For some patients, several samples drawn during the follow-up could be analyzed.

Results: Using the photonic ring immunoassay, we could confirm the presence of anti-MDA5 antibody in all samples known as positive for anti-MDA5 antibody by other techniques. No false positive or false negative results were found. Moreover, high levels of MDA-5 antibodies measured at diagnosis are associated withinterstitial lung disease with respiratory functional impairment at presentation. Interstingly, we observed a decrease in anti-MDA5 antibodies titers in followed-up patients.

Conclusion: The photonic ring immunoassay is a fast and reliable technology for the detection of anti-MDA5 antibodies.


Disclosure: M. Miyara, Genalyte, 5; R. Chieze, None; Y. Uzunhan, None; J. L. Charuel, None; P. Ghillani-Dalbin, None; S. Mudumba, None; A. Wu, Genalyte, 3; H. Nunes, None; Z. Amoura, None; R. Burlingame, None; L. Musset, None.

To cite this abstract in AMA style:

Miyara M, Chieze R, Uzunhan Y, Charuel JL, Ghillani-Dalbin P, Mudumba S, Wu A, Nunes H, Amoura Z, Burlingame R, Musset L. Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/near-patient-detection-of-anti-mda5-antibodies-using-photonic-ring-immunoassays/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/near-patient-detection-of-anti-mda5-antibodies-using-photonic-ring-immunoassays/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology